Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,300 JPY | -1.15% |
|
-.--% | +8.18% |
24/06 | Hutchmed China notes Takeda obtains EU approval for Fruzaqla | AN |
24/06 | Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 46.05 and 70.65 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.18% | 40.23B | - | ||
+52.70% | 801B | C+ | ||
+41.58% | 631B | B | ||
-4.86% | 359B | C+ | ||
+21.96% | 337B | B- | ||
+11.47% | 305B | C+ | ||
+17.72% | 245B | B+ | ||
+4.46% | 231B | A+ | ||
+13.13% | 219B | B- | ||
+10.46% | 171B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock
- Ratings Takeda Pharmaceutical Company Limited